SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.

导出 OA

翻译打印收藏纠错

作者： Evangelos,Terpos ^[1] ; Despina,Fotiou ^[1] ; Vangelis,Karalis ^[2] ; Ioannis,Ntanasis-Stathopoulos ^[1] ; Aimilia D,Sklirou ^[3] ; Maria,Gavriatopoulou ^[1] ; Panagiotis,Malandrakis ^[1] ; Vassiliki A,Iconomidou ^[3] ; Efstathios,Kastritis ^[1] ; Ioannis P,Trougakos ^[3] ; Meletios A,Dimopoulos ^[1]

作者单位： Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. ^[1] Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece. ^[2] Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. ^[3]

主题词抗体, 病毒(Antibodies, Viral);人类(Humans);肿瘤(Neoplasms);接种(Vaccination)

DOI 10.1002/ajh.26669

PMID 35871310

发布时间 2023-01-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交